Community-acquired pneumonia (CAP) questions are some of the highest-yield “pattern recognition + management” vignettes on Step 1 and Step 2. The trick isn’t just picking the right bug or antibiotic—it’s knowing why every other answer choice is wrong based on timeline, setting, exam, and risk factors. Let’s break down a classic Q-bank style case and then autopsy each distractor like you’re reviewing your missed questions the right way.
Clinical Vignette (Q-bank style)
A 57-year-old man comes to the ED with 2 days of fever, chills, productive cough, and right-sided pleuritic chest pain. He has a history of COPD and type 2 diabetes. He is not on home oxygen. He has not been hospitalized in the past year.
Vitals: T 38.8°C (101.8°F), HR 108, BP 128/74, RR 24, SpO₂ 92% on room air.
Exam: decreased breath sounds and crackles over the right lower lung field.
CXR: right lower lobe consolidation.
Which is the best empiric outpatient antibiotic regimen?
A. Amoxicillin-clavulanate + azithromycin
B. Azithromycin alone
C. Amoxicillin alone
D. Piperacillin-tazobactam
E. Oseltamivir
Step-wise Approach (how to think, not just what to pick)
1) Is this CAP?
Yes—this is an acute pneumonia syndrome with:
- Fever + cough + pleuritic pain
- Lobar consolidation on CXR (classic “typical” bacterial pattern)
- No recent hospitalization → not hospital-acquired/ventilator-associated
2) Decide outpatient vs inpatient
He’s borderline but plausible outpatient depending on stability and scoring.
High-yield tools:
- CURB-65: Confusion, Urea > 20, RR ≥ 30, BP low, Age ≥ 65
- PSI (more detailed)
He’s 57, RR 24, BP okay, no confusion—so outpatient is reasonable if he can take PO, has support, and no severe features.
3) Choose empiric outpatient therapy based on comorbidities
He has COPD and diabetes, which bumps him into the “outpatient with comorbidities” bucket.
High-yield regimen (IDSA/ATS-style board framing):
- Beta-lactam + macrolide
or - Respiratory fluoroquinolone monotherapy (e.g., levofloxacin, moxifloxacin)
That makes A the best answer.
Correct Answer: A. Amoxicillin-clavulanate + azithromycin
Why it’s correct
For outpatient CAP with comorbidities, you want to cover:
- Typical bacteria: Streptococcus pneumoniae (most important), H influenzae, Moraxella catarrhalis
- Atypicals: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella (less common outpatient but a test favorite)
Amoxicillin-clavulanate
- Strong for many typical respiratory pathogens
- Clavulanate adds beta-lactamase coverage (helpful in COPD-related flora)
Azithromycin
- Covers “atypicals” and adds pneumococcal coverage (though resistance exists)
Board takeaway: In CAP, single-agent therapy is only safe in the right patient. Comorbidities push you toward broader empiric coverage.
Why Each Distractor Is Wrong (and what it’s testing)
B. Azithromycin alone
Why it’s tempting: You remember “macrolide = CAP outpatient.”
Why it’s wrong here:
- Macrolide monotherapy is generally for healthy outpatients with no comorbidities and low local pneumococcal resistance.
- In patients with COPD/DM, risk of drug-resistant S. pneumoniae and other typicals is higher → you need a beta-lactam partner (or use a respiratory fluoroquinolone).
High-yield pearl:
If the question gives comorbidities (COPD, DM, alcoholism, immunosuppression) or recent antibiotics, think combo therapy or respiratory FQ.
C. Amoxicillin alone
Why it’s tempting: S. pneumoniae is the most common CAP cause, and amoxicillin is a classic pneumococcal drug.
Why it’s wrong here:
- Amoxicillin alone doesn’t reliably cover atypicals.
- In comorbid patients, you want broader “typicals + atypicals” coverage.
When amoxicillin alone can be right (test nuance):
- A healthy outpatient with mild CAP and no comorbidities (depending on local guidelines), where pneumococcus is the prime target.
High-yield pearl:
Atypical coverage matters most when the stem hints at:
- Dry cough, low-grade fever, outpatient walking pneumonia (Mycoplasma)
- GI symptoms, hyponatremia, confusion, recent travel/hotel/water exposure (Legionella)
But even without those clues, comorbidities often push you into combo coverage.
D. Piperacillin-tazobactam
Why it’s tempting: Broad-spectrum = “safer,” right?
Why it’s wrong:
- This is overkill for standard outpatient CAP.
- Piptazo is mainly for suspected hospital-acquired pathogens including Pseudomonas and other gram-negatives.
When to think Pseudomonas coverage (high-yield):
- Structural lung disease (severe bronchiectasis), frequent exacerbations with antibiotics
- Prior respiratory culture with Pseudomonas
- Recent hospitalization with IV antibiotics (often within ~90 days in older frameworks)
- Ventilator-associated or hospital-acquired pneumonia context
Board takeaway: CAP ≠ “use the biggest gun.” CAP management is about risk stratification.
E. Oseltamivir
Why it’s tempting: Fever + cough in winter makes people think influenza.
Why it’s wrong here:
- The case gives lobar consolidation and productive cough suggesting bacterial pneumonia.
- Influenza can cause pneumonia, but classic flu is more:
- Abrupt onset, myalgias, headache
- Often initially nonproductive cough
- CXR may be diffuse/interstitial rather than focal lobar consolidation
Key nuance they love to test:
Influenza can predispose to secondary bacterial pneumonia—especially Staph aureus (including MRSA), S. pneumoniae, and H. influenzae. Clues include:
- Patient improves from flu then worsens again (“biphasic illness”)
- High fever, productive cough, focal consolidation
- Consider adding MRSA coverage (e.g., vancomycin/linezolid) in severe cases with risk factors
High-Yield CAP Micro Patterns (when they ask “most likely organism”)
| Clue | Likely pathogen | Buzzwords |
|---|---|---|
| Lobar consolidation, rusty sputum | Streptococcus pneumoniae | Most common CAP |
| COPD, smoker | H. influenzae, Moraxella | Beta-lactamase producers (esp Moraxella) |
| Post-influenza, cavitary lesions | Staph aureus | Can be MRSA; necrotizing pneumonia |
| Aspiration risk (alcohol use, seizures, stroke) | Anaerobes (mixed flora) | Foul-smelling sputum, lower lobes |
| GI symptoms, hyponatremia, relative bradycardia | Legionella | Water exposure, hotels, AC systems |
| Walking pneumonia, dry cough | Mycoplasma | Cold agglutinins, young adults |
High-Yield CAP Management Rules (Step 2 gold)
When is CAP “severe”?
Major criteria (either one suggests ICU):
- Mechanical ventilation
- Septic shock requiring vasopressors
Minor criteria (multiple suggests ICU consideration):
- RR ≥ 30, PaO₂/FiO₂ ≤ 250, multilobar infiltrates
- Confusion, BUN ≥ 20, leukopenia, thrombocytopenia, hypothermia, hypotension requiring fluids
Typical empiric inpatient regimens (non-ICU)
- Beta-lactam (e.g., ceftriaxone) + macrolide, or
- Respiratory fluoroquinolone
Add-on coverage when indicated
- MRSA risk → vancomycin or linezolid
- Pseudomonas risk → anti-pseudomonal beta-lactam (e.g., piperacillin-tazobactam, cefepime, meropenem) + second agent depending on severity/local patterns
Quick “Why Every Choice Matters” Summary
- A (Correct): Comorbid outpatient CAP → beta-lactam + macrolide (or respiratory FQ).
- B: Too narrow in comorbid patients; macrolide monotherapy is for healthier, low-resistance settings.
- C: Misses atypicals; okay only in select low-risk outpatients.
- D: Overbroad; reserved for suspected Pseudomonas/HAP contexts.
- E: Antiviral doesn’t treat bacterial lobar CAP; consider only if primary influenza is likely (or alongside antibiotics if flu + secondary bacterial pneumonia suspected).
Tag
Pulmonary > Pulmonary Infections